Paige

Sometimes less is more.

Thank you for using your voices. ~patients in Texas

Thread!

Good news for #lobular: @theaacr.bsky.social #AACR25 now has an Advances session on ILC!

AOS12 - New Findings in Invasive Lobular Breast Cancer: Histology Matters
www.abstractsonline.com/pp8/#!/20273...

Excited to be the intermission btw Steffi Oesterreich & Christina Curtis 😅. See you in Chicago!

The ordinarily cautious and conservative ABA is blowing the whistle: The break-the-glass moment has arrived.
www.americanbar.org/news/abanews...

Child with alopecia from chemotherapy

When Elon was a kid, survival for ALL, the most common childhood cancer, was <10%

Now it’s >90% due to funded collaboratives (high indirect costs) whose work ultimately SAVES THOUSANDS OF LIVES EVERY YEAR.

For other cancers there’s still so much progress to be made.

I think it’s worth it.

@tribelaw.bsky.social

Contact your representatives- make sure they know what the impact of this is. #NIHsky #cansky #oncsky #IDsky

Don't miss this recent review outlining practical treatment strategies and novel therapies in the PI3K/AKT/mTOR pathway in HR+/HER2- advanced #BreastCancer
🔓 pubmed.ncbi.nlm.nih.gov/39674130/
@antgiordanomd.bsky.social @drtimothyerick.bsky.social @stolaney1.bsky.social @drsarahsammons.bsky.social

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor re...

Now online in JCO #postMonarch

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky

I'm excited to see ELBCC join the blue space! 🎉 Check out the terrific presentations from the #ILCSymposium 2024 in Leuven, which are all now available: youtube.com/@elbcc.europ..

What’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatment More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks and tools to take down b...

Did you miss #SABCS24 last week? No worries! Here's my @fredhutch.bsky.social SABCS24 wrap story w/insights into #cancer treatments & #cannabis; #ctDNA; #obesity & #epigenetics, #FES-PET & much more. #cansky #oncocsky #medsky #bcsm @thankscancer.bsky.social

www.fredhutch.org/en/news/cent...

Thank you to all of the advocates and researchers/scientists who shared throughout the week from SA. Information is power and you are giving patients power when you share. #bcsm #oncsky

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @oncoalert.bsky.social

Dr Kaelin gave a very thought provoking talk.

He argues single agent therapies will never cure cancer due to resistance.

Our chance is cure will come with multiple non-cross resistant therapies, challenging current paradigms.

#bcsm

When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!

“ChatGPT can be used for more than college students cheating on essays” Dr Erika Hamilton explains how Sarah Cannon uses this to match patients to trials. #SABCS24

Great women doing great work!

RLY2608 is a mutant specific PIK3CA inhibitor sparing Wildtype Receptor.

2nd line PFS >11 months with fulvestrant.

Improved safety profile with low grade hyperglycemia, no rash, diarrhea, or oral sores.

Hoping this one moves forward!

#SABCS24 @oncoalert.bsky.social @oncbrothers.bsky.social

🧩How could these puzzle pieces fit? @DrHBurstein suggests one approach ⬇️ #SABCS24 @oncoalert.bsky.social

#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm

Dr. Rinath Jeselsohn discusses #SERDS and the targeting of ER and #PI3K pathway in the #SABCS24 Poster Spotlight Session.

Wander around*

Such important information. But what about in the MBC setting with ER+ disease. Especially with ILC that loves to wonder around the pelvic area.

For patients and doctors, insurance prior authorization can be a dangerous game | Opinion Doctors trying to get patients necessary drugs and procedures stymied by health insurance prior authorization. It's not a game. It's life and death.

"For both patients and providers, prior authorization can feel like an unfair game they are designed to lose."

Honored to work w/ Dr @nathangray.bsky.social on a graphic op-ed out now @usatoday.com on how #PriorAuth can leave some patients literally dying in pain.

www.usatoday.com/story/opinio...

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast Invasive lobular carcinoma of the breast (ILC) are typically estrogen receptor α (ER)-positive and present with biomarkers of anti-estrogen sensitive disease, yet patients with ILC face uniquely poor ...

Exciting update to our #lobular breast cancer work with DNA repair and PARP inhibition, ahead of @sabcs.bsky.social next week! #oncosky #bcsm
www.biorxiv.org/content/10.1...

Despite lacking "BRCA-like" mutations and features, we find ILC models are sensitive to PARPi in vivo. Why? 🧵 1/n

Home welcome to the sikora lab

Hey #oncosky and 🧪 friends - so glad you're here!
A quick (re)intro to the Sikora Lab (www.sikoralab.com):
We study:
1) #lobular breast cancer and its complicated relationship w estrogen.
2) gyn / ovarian cancer, metabolic parallels w #lobular, and genetic links to health disparities.

1/n

More #thinkibc inflammatory breast cancer community on 🦋🦋 #bcsm Now the incomparable Dr. Lim!! #oncsky @talkibc.bsky.social @mdanderson.bsky.social @debeblab.bsky.social 🎉🎉

A maroon origami crane made out of paper on a clipboard next to a fancy pen.

Folded my 1st cranes for pts completing #radiation this week MD Anderson.

I fold cranes as a small private gesture as a bell alternative; when I give them I explain they are a symbol of hope & healing. Paper -like hope- is both fragile & incredibly strong. It's a tiny thing but I do it with love. ❤️